Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Zacks Investment Research


Share on StockTwits

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports.

According to Zacks, “Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. “

ARCT has been the subject of several other research reports. B. Riley increased their price objective on shares of Arcturus Therapeutics from $64.00 to $111.00 and gave the company a “buy” rating in a research note on Monday, December 7th. Roth Capital downgraded shares of Arcturus Therapeutics from a “buy” rating to a “sell” rating and set a $77.00 price objective for the company. in a research note on Wednesday, December 23rd. Smith Barney Citigroup raised their price target on shares of Arcturus Therapeutics from $62.00 to $133.00 in a research note on Monday, December 14th. Citigroup began coverage on shares of Arcturus Therapeutics in a research note on Tuesday, October 6th. They set a “buy” rating and a $65.00 price target for the company. Finally, HC Wainwright downgraded shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $84.00 to $50.00 in a research note on Tuesday, December 29th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $70.40.

Shares of NASDAQ ARCT traded up $2.40 during trading hours on Wednesday, hitting $65.29. 47,179 shares of the stock were exchanged, compared to its average volume of 3,457,503. The company has a debt-to-equity ratio of 0.06, a quick ratio of 11.21 and a current ratio of 11.21. The company has a market cap of $1.60 billion, a PE ratio of -22.51 and a beta of 3.01. The company’s fifty day simple moving average is $84.01 and its two-hundred day simple moving average is $58.65. Arcturus Therapeutics has a 1-year low of $8.51 and a 1-year high of $129.71.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Saturday, November 14th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.43). The firm had revenue of $2.33 million for the quarter, compared to analyst estimates of $3.17 million. Arcturus Therapeutics had a negative return on equity of 52.32% and a negative net margin of 506.70%. As a group, sell-side analysts expect that Arcturus Therapeutics will post -3.14 EPS for the current fiscal year.

In other news, COO Pad Chivukula sold 10,000 shares of Arcturus Therapeutics stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $55.28, for a total transaction of $552,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ultragenyx Pharmaceutical Inc. sold 442,255 shares of Arcturus Therapeutics stock in a transaction dated Tuesday, December 8th. The shares were sold at an average price of $105.54, for a total transaction of $46,675,592.70. Following the transaction, the director now owns 2,557,745 shares of the company’s stock, valued at $269,944,407.30. The disclosure for this sale can be found here. Insiders sold 462,255 shares of company stock valued at $47,692,393 over the last 90 days. Corporate insiders own 12.60% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Great West Life Assurance Co. Can acquired a new position in shares of Arcturus Therapeutics during the second quarter valued at about $54,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Arcturus Therapeutics by 119.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,722 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 936 shares in the last quarter. Advisor Group Holdings Inc. increased its holdings in Arcturus Therapeutics by 191.2% in the 2nd quarter. Advisor Group Holdings Inc. now owns 1,747 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 1,147 shares in the last quarter. Point72 Hong Kong Ltd grew its holdings in shares of Arcturus Therapeutics by 15,106.7% during the third quarter. Point72 Hong Kong Ltd now owns 2,281 shares of the biotechnology company’s stock worth $98,000 after buying an additional 2,266 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Arcturus Therapeutics by 733.3% during the third quarter. BNP Paribas Arbitrage SA now owns 4,133 shares of the biotechnology company’s stock worth $177,000 after buying an additional 3,637 shares in the last quarter. Hedge funds and other institutional investors own 74.33% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology.

Further Reading: Do stock splits help investors?

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.